Products Categories
CAS No.: | 103890-78-4 |
---|---|
Name: | Lacidipine |
Article Data: | 7 |
Molecular Structure: | |
Formula: | C26H33NO6 |
Molecular Weight: | 455.551 |
Synonyms: | 3,5-Pyridinedicarboxylicacid,4-[2-[(1E)-3-(1,1-dimethylethoxy)-3-oxo-1-propen-1-yl]phenyl]-1,4-dihydro-2,6-dimethyl-,3,5-diethyl ester;3,5-Pyridinedicarboxylicacid,4-[2-[(1E)-3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-,diethyl ester (9CI);3,5-Pyridinedicarboxylic acid,4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-,diethyl ester, (E)-;Lacimen;Lacipil;Lacirex;Midotens;Motens; |
EINECS: | 638-759-0 |
Density: | 1.127 g/cm3 |
Melting Point: | 174-175 °C |
Boiling Point: | 558.4 °C at 760 mmHg |
Flash Point: | 291.5 °C |
Appearance: | White-to-off-white crystalline solid |
Hazard Symbols: | Xn |
Risk Codes: | 22 |
PSA: | 90.93000 |
LogP: | 4.73130 |
The Lacidipine with CAS registry number of 103890-78-4 is also known as 3,5-Pyridinedicarboxylicacid,4-[2-[(1E)-3-(1,1-dimethylethoxy)-3-oxo-1-propen-1-yl]phenyl]-1,4-dihydro-2,6-dimethyl-,3,5-diethyl ester. The IUPAC name is Diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate. It belongs to product categories of Active Pharmaceutical Ingredients; Dihydropyridine Class Chemicals; Intermediates & Fine Chemicals; Pharmaceuticals; Calcium channel. In addition, the formula is C26H33NO6 and the molecular weight is 455.55. This chemical is a white-to-off-white crystalline solid that can be used as a dihydropyridine calcium channel blocker and antihypertensive.
Physical properties about Lacidipine are:
(1)ACD/LogP: 5.49; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): 5.48; (4)ACD/LogD (pH 7.4): 5.48; (5)ACD/BCF (pH 5.5): 8653.93; (6)ACD/BCF (pH 7.4): 8680.73; (7)ACD/KOC (pH 5.5): 22880.25; (8)ACD/KOC (pH 7.4): 22951.11; (9)#H bond acceptors: 7; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 11; (12)Index of Refraction: 1.54; (13)Molar Refractivity: 126.78 cm3; (14)Molar Volume: 403.9 cm3; (15)Surface Tension: 40.7 dyne/cm; (16)Density: 1.127 g/cm3; (17)Flash Point: 291.5 °C; (18)Enthalpy of Vaporization: 84.05 kJ/mol; (19)Boiling Point: 558.4 °C at 760 mmHg; (20)Vapour Pressure: 1.67E-12 mmHg at 25 °C.
Preparation of Lacidipine:
Firstly, o-benzenedimethanal is mixed with triphenyl phosphine acetic acid tert-butyl to generate 3-(2-formyl-phenyl) acrylic acid tert-butyl. The reaction needs solvent dichloromethane at 0 °C for 15 minutes. Then 3-(2-formyl-phenyl) acrylic acid tert-butyl reacts with 2-amino-2-butene ethyl and solvent acetic acid for 5 hours at room temperature to obtain product.
You can still convert the following datas into molecular structure:
1. Canonical SMILES: CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C
2. Isomeric SMILES: CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C
3. InChI: InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
4. InChIKey: GKQPCPXONLDCMU-CCEZHUSRSA-N
The toxicity data of Lacidipine is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 80200ug/kg (80.2mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22, Pg. 335, 1994. |
mouse | LD50 | oral | 3150mg/kg (3150mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22, Pg. 335, 1994. |
mouse | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22, Pg. 335, 1994. | |
rat | LD50 | intraperitoneal | 43300ug/kg (43.3mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22, Pg. 335, 1994. |
rat | LD50 | oral | 880mg/kg (880mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22, Pg. 335, 1994. |
rat | LD50 | subcutaneous | 562mg/kg (562mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22, Pg. 335, 1994. |